S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 40 of 48

Issue Date	Title / Author(s) / Citation	File
2005	Predictive and prognostic impact of epidermal growth factor receptor (EGFR) mutation in non-small-cell lung cancer (NSCLC) patients treated with gefitinib (ZD1839) 한세원	link
2005-01	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer Han, Sae-Won; Hwang, Pil Gyu; Chung, Doo Hyun; Kim, Dong-Wan; Im, Seock-Ah; Kim, Young Tae; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong International Journal of Cancer, Vol.113 No.1, pp.109-115	DOI
2005-07	Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer Kim, Dae-Young; Lee, Keun-Wook; Yun, Tak; Kim, Dong-Wan; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong Oncology Reports, Vol.14 No.1, pp.207-211	DOI
2007-11	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives Kim, Toe-You; Han, Soe-Won; Bang, Yung-Jue Expert Review of Molecular Diagnostics, Vol.7 No.6, pp.821-836	DOI
2008	Prognostic factors of non-small cell lung cancer with bone metastasis 배현미	link
2012-09	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis Bae, Hyun-Mi; Lee, Se-Hoon; Kim, Tae Min; Kim, Dong-Wan; Yang, Seok-Chul; Wu, Hong Gyun; Kim, Young Whan; Heo, Dae Seog Lung Cancer, Vol.77 No.3, pp.572-577	DOI
2012-12	Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients Lee, Joo Ho; Wu, Hong-Gyun; Kim, Hak Jae; Kim, Dong-Wan; Lee, Se-Hoon; Kim, Tae Min; Kim, Young Whan; Heo, Dae Seog Cancer Research and Treatment, Vol.44 No.4, pp.242-250	view file DOI
2015-02	Ring-truncated deguelin analogue induces apoptosis and anti-angiogenesis in non-small cell lung carcinoma cells 최훈	view file
2015-05	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Blumenschein, G. R., Jr.; Smit, E. F.; Planchard, D.; Kim, D. -W.; Cadranel, J.; De Pas, T.; Dunphy, F.; Udud, K.; Ahn, M. -J.; Hanna, N. H.; Kim, J. -H.; Mazieres, J.; Kim, S. -W.; Baas, P.; Rappold, E.; Redhu, S.; Puski, A.; Wu, F. S.; Jaenne, P. A. Annals of Oncology, Vol.26 No.5, pp.894-901	DOI
2015-11	Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells Oh, Se Jin; Noh, Kyung Hee; Lee, Young-Ho; Hong, Soon-Oh; Song, Kwon-Ho; Lee, Hyo-Jung; Kim, Soyeon; Kim, Tae Min; Jeon, Ju-Hong; Seo, Jae Hong; Kim, Dong-Wan; Kim, Tae Woo Oncotarget, Vol.6 No.37, pp.40255-40267	view file DOI
2016-02	A Novel Synthetic Derivative of Deguelin, SH-174, Exhibits Anti-cancer Activities Against Non-small-cell Lung Cancer Cells 김준용	view file
2016-02	Biological Screening of Natural Compounds for Developing Anticancer Agents in Non-Small Cell Lung Cancer 정유진	view file
2016-02	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee, Ji Yun; Xu Qing; Wei Xiumin; Bai Yali; Chi, Sangah; Bak, So Hyeon; Lee, Ho Yun; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Hye Ryun; Min, Young Joo; Jung, Sin-Ho; Park, Keunchil; Mao Mao; Ahn, Myung-Ju Oncotarget, Vol.7 No.6, pp.6984-6993	view file DOI
2016-03	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. Annals of Oncology, Vol.27 No.3, pp.417-423	DOI
2016-04	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto, Jr.; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B. The Lancet, Vol.387 No.10027, pp.1540-1550	DOI
2016-05	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Arvis Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis The Lancet Oncology, Vol.17 No.5, pp.577-589	DOI
2016-07	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer Han, Jae Joon; Kim, Dong-Wan; Koh, Jaemoon; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Clinical Lung Cancer, Vol.17 No.4, pp.263-270	DOI
2017-02	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Paz-Ares, L.; Tan, E. -H.; O'Byrne, K.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J. C. -H.; Mok, T.; Lee, K. H.; Lu, S.; Shi, Y.; Lee, D. H.; Laskin, J.; Kim, D. -W.; Laurie, S. A.; Kolbeck, K.; Fan, J.; Dodd, N.; Marten, A.; Park, K. Annals of Oncology, Vol.28 No.2, pp.270-277	DOI
2017-03	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer Shin, Junghoon; Keam, Bhumsuk; Kim, Miso; Park, Young Sik; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.12 No.3, pp.520-528	DOI
2017-08	Scientific Advances in Thoracic Oncology 2016 Soo, Ross A.; Stone, Emily C. A.; Cummings, K. Michael; Jett, James R.; Field, John K.; Groen, Harry J. M.; Mulshine, James L.; Yatabe, Yasushi; Bubendorf, Lukas; Dacic, Sanja; Rami-Porta, Ramon; Detterbeck, Frank C.; Lim, Eric; Asamura, Hisao; Donington, Jessica; Wakelee, Heather A.; Wu, Yi-Long; Higgins, Kristin; Senan, Suresh; Solomon, Benjamin; Kim, Dong-Wan; Johnson, Melissa; Yang, James C. H.; Sequist, Lecia V.; Shaw, Alice T.; Ahn, Myung-Ju; Costa, Daniel B.; Patel, Jyoti D.; Horn, Leora; Gettinger, Scott; Peters, Solange; Wynes, Murry W.; Faivre-Finn, Corinne; Rudin, Charles M.; Tsao, Anne; Baas, Paul; Kelly, Ronan J.; Leighl, Natasha B.; Scagliotti, Giorgio V.; Gandara, David R.; Hirsch, Fred R.; Spigel, David R. Journal of Thoracic Oncology, Vol.12 No.8, pp.1183-1209	DOI
2017-09	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Suh, Koung Jin; Sung, Ji Hea; Kim, Jin Won; Han, Song-Hee; Lee, Hye Seung; Min, Ahrum; Kang, Mi Hyun; Kim, Ji Eun; Kim, Ji-Won; Kim, Se Hyun; Lee, Jeong-Ok; Kim, Yu Jung; Lee, Keun-Wook; Kim, Jee Hyun; Bang, Soo-Mee; Im, Seock-Ah; Lee, Jong Seok Oncotarget, Vol.8 No.38, pp.63901-63910	DOI
2017-09	ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) Cho, Byoung Chul; Kim, Dong-Wan; Bearz, Alessandra; Laurie, Scott A.; McKeage, Mark; Borra, Gloria; Park, Keunchil; Kim, Sang-We; Ghosn, Marwan; Ardizzoni, Andrea; Maiello, Evaristo; Greystoke, Alastair; Yu, Richard; Osborne, Karen; Gu, Wen; Scott, Jeffrey W.; Passos, Vanessa Q.; Lau, Yvonne Y.; Wrona, Anna Journal of Thoracic Oncology, Vol.12 No.9, pp.1357-1367	DOI
2017-09	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gandhi, Leena; Ou, Sai-Hong Ignatius; Shaw, Alice T.; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Kim, Dong-Wan; Camidge, D. Ross; Hughes, Brett G. M.; Yang, James C. -H.; de Castro, Javier; Crino, Lucio; Lena, Herve; Do, Pascal; Golding, Sophie; Bordogna, Walter; Zeaiter, Ali; Kotb, Ahmed; Gadgeel, Shirish European Journal of Cancer, Vol.82, pp.27-33	DOI
2018-04	Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer Felip, Enriqueta; Barlesi, Fabrice; Besse, Benjamin; Chu, Quincy; Gandhi, Leena; Kim, Sang-We; Carcereny, Enric; Sequist, Lecia V.; Brunsvig, Paal; Chouaid, Christos; Smit, Egbert F.; Groen, Harry J. M.; Kim, Dong-Wan; Park, Keunchil; Avsar, Emin; Szpakowski, Sebastian; Akimov, Mikhail; Garon, Edward B. Journal of Thoracic Oncology, Vol.13 No.4, pp.576-584	DOI
2018-04	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Garassino, Marina Chiara; Cho, Byoung-Chul; Kim, Joo-Hang; Mazieres, Julien; Vansteenkiste, Johan; Lena, Herve; Jaime, Jesus Corral; Gray, Jhanelle E.; Powderly, John; Chouaid, Christos; Bidoli, Paolo; Wheatley-Price, Paul; Park, Keunchil; Soo, Ross A.; Huang, Yifan; Wadsworth, Catherine; Dennis, Phillip A.; Rizvi, Naiyer A.; ATLANTIC Investigators; Kim, Dong Wan The Lancet Oncology, Vol.19 No.4, pp.521-536	DOI
2018-07	Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer Nishio, Makoto; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Solomon, Benjamin J.; Shaw, Alice T.; Hashigaki, Satoshi; Ohki, Emiko; Usari, Tiziana; Paolini, Jolanda; Polli, Anna; Wilner, Keith D.; Mok, Tony Cancer Research and Treatment, Vol.50 No.3, pp.691-700	view file DOI
2018-11	Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study Gadgeel, S.; Peters, S.; Mok, T.; Shaw, A. T.; Kim, D. W.; Ou, S. I.; Perol, M.; Wrona, A.; Novello, S.; Rosell, R.; Zeaiter, A.; Liu, T.; Nuesch, E.; Balas, B.; Camidge, D. R. Annals of Oncology, Vol.29 No.11, pp.2214-2222	DOI
2019-05	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC Barlesi, Fabrice; Garon, Edward B.; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; de Castro, Gilberto, Jr.; Surmont, Veerle; Li, Qiao; Deitz, Anne C.; Lubiniecki, Gregory M.; Herbst, Roy S. Journal of Thoracic Oncology, Vol.14 No.5, pp.793-801	DOI
2019-06	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Schuler, Martin; Tan, Eng-Huat; O'Byrne, Kenneth; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Massey, Dan; Maerten, Angela; Paz-Ares, Luis; Park, Keunchil Journal of Cancer Research and Clinical Oncology, Vol.145 No.6, pp.1569-1579	DOI
2019-07	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451	DOI
2019-09	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566	DOI
2019-10	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC Antonia, Scott J.; Balmanoukian, Ani; Brahmer, Julie; Ou, Sai-Hong I.; Hellmann, Matthew D.; Kim, Sang-We; Ahn, Myung-Ju; Kim, Dong-Wan; Gutierrez, Martin; Liu, Stephen V.; Schoffski, Patrick; Jaeger, Dirk; Jamal, Rahima; Jerusalem, Guy; Lutzky, Jose; Nemunaitis, John; Calabro, Luana; Weiss, Jared; Gadgeel, Shirish; Bhosle, Jaishree; Ascierto, Paolo A.; Rebelatto, Marlon C.; Narwal, Rajesh; Liang, Meina; Xiao, Feng; Antal, Joyce; Abdullah, Shaad; Angra, Natasha; Gupta, Ashok K.; Khleif, Samir N.; Segal, Neil H. Journal of Thoracic Oncology, Vol.14 No.10, pp.1794-1806	DOI
2020-01	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou, Sai-Hong Ignatius; Gadgeel, Shirish M.; Barlesi, Fabrice; Yang, James Chih-Hsin; De Petris, Luigi; Kim, Dong-Wan; Govindan, Ramaswamy; Dingemans, Anne-Marie; Crino, Lucio; Lena, Herve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Mitry, Emmanuel; Mueller, Barbara; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Shaw, Alice T. Lung Cancer, Vol.139, pp.22-27	DOI
2020-03	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis Cho, Byoung Chul; Kim, Dong-Wan; Park, Keunchil; Lee, Jong-Seok; Yoo, Seung Soo; Kang, Jin Hyoung; Lee, Sung Yong; Kim, Cheol Hyeon; Jang, Seung Hun; Kim, Young-Chul; Yoon, Hyoung-Kyu; Han, Ji-Youn; Kim, Sang-We Current Medical Research and Opinion, Vol.36 No.3, pp.477-482	DOI
2020-09	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC Zhu, Viola W.; Lin, Yen-Ting; Kim, Dong-Wan; Loong, Herbert H.; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L.; Reungwetwattana, Thanyanan; Lin, Chia-Chi; Soo, Ross A. Journal of Thoracic Oncology, Vol.15 No.9, pp.1484-1496	DOI
2021	The effect of AQP3 on intercellular adhesion in NSCLC A549 cell spheroids through cell protrusions 민솔	view file link
2021-02	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study Mok, Tony; Peters, Solange; Camidge, D. Ross; Noe, Johannes; Gadgeel, Shirish; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Konopa, Krzysztof; Pozzi, Emanuela; Liu, Ting; Loftin, Isabell R.; Williams, Crystal; Shaw, Alice T. Journal of Thoracic Oncology, Vol.16 No.2, pp.259-268	DOI
2021-04	AQP3 Increases Intercellular Cohesion in NSCLC A549 Cell Spheroids through Exploratory Cell Protrusions Min, Sol; Choe, Chungyoul; Roh, Sangho International Journal of Molecular Sciences, Vol.22 No.8, p. 4287	DOI
2021-10	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Park, Keunchil; Haura, Eric B.; Leighl, Natasha B.; Mitchell, Paul; Shu, Catherine A.; Girard, Nicolas; Viteri, Santiago; Han, Ji-Youn; Kim, Sang-We; Lee, Chee Khoon; Sabari, Joshua K.; Spira, Alexander, I; Yang, Tsung-Ying; Kim, Dong Wan; Lee, Ki Hyeong; Sanborn, Rachel E.; Trigo, Jose; Goto, Koichi; Lee, Jong Seok; Yang, James Chih-Hsin; Govindan, Ramaswamy; Bauml, Joshua M.; Garrido, Pilar; Krebs, Matthew G.; Reckamp, Karen L.; Xie, John; Curtin, Joshua C.; Haddish-Berhane, Nahor; Roshak, Amy; Millington, Dawn; Lorenzini, Patricia; Thayu, Meena; Knoblauch, Roland E.; Cho, Byoung Chul Journal of Clinical Oncology, Vol.39 No.30, pp.3391-3402	DOI
2021-11	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC Park, Ha-Ram; Kim, Tae Min; Lee, Yusoo; Kim, Soyeon; Park, Seongyeol; Ju, Young Seok; Kim, Miso; Keam, Bhumsuk; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.16 No.11, pp.1859-1871	DOI

1 2